Kids First Participant ID	Kids First Biospecimen ID	CBTN ID	Phase of therapy	Therapy post-biopsy	Cancer predisposition(s)	TMB	Composition	OpenPBTA molecular subtype
PT_0SPKM4S8	BS_VW4XN9Y7	7316-2640	Initial CNS Tumor	Temozolomide, CCNU, Radiation	None documented	187.38765454966892	Solid Tissue	HGG, H3 wildtype, TP53 activated
PT_3CHB9PK5	BS_20TBZG09	7316-515	Initial CNS Tumor	Temozolomide, Irinotecan, Bevacizumab, Radiation	NF-1,Other inherited conditions NOS	307.0492167109247	Solid Tissue	HGG, H3 wildtype, TP53 loss
PT_3CHB9PK5	BS_8AY2GM4G	7316-2085	Progressive	Unknown	NF-1, Lynch syndrome, pathogenic MSH6	321.6079467820181	Solid Tissue	HGG, H3 wildtype, TP53 loss
PT_JNEV57VK	BS_85Q5P8GF	7316-2594	Initial CNS Tumor	Temozolomide, Radiation	Lynch syndrome	4.731587273105341	Solid Tissue	DMG, H3 K28, TP53 loss
PT_JNEV57VK	BS_HM5GFJN8	7316-3058	Progressive	Nivolumab	Lynch Syndrome, pathogenic MSH2	35.89286913681093	Derived Cell Line	DMG, H3 K28, TP53 loss
PT_JNEV57VK	BS_QWM9BPDY	7316-3058	Progressive	Nivolumab	Lynch Syndrome, pathogenic MSH2	7.363357709033756	Derived Cell Line	DMG, H3 K28, TP53 loss
PT_JNEV57VK	BS_P0QJ1QAH	7316-3058	Progressive	Nivolumab	Lynch Syndrome, pathogenic MSH2	6.271452953701754	Solid Tissue	DMG, H3 K28, TP53 activated
PT_S0Q27J13	BS_P3PF53V8	7316-2307	Initial CNS Tumor	Temozolomide, Irinotecan, Radiation	None documented	15.482649479451206	Solid Tissue	HGG, H3 wildtype, TP53 activated
PT_VTM2STE3	BS_ERFMPQN3	7316-2189	Progressive	Unknown	Lynch Syndrome	5.739499354950266	Derived Cell Line	HGG, H3 wildtype, TP53 loss
PT_VTM2STE3	BS_02YBZSBY	7316-2189	Progressive	Unknown	Lynch Syndrome	274.48805695576783	Solid Tissue	HGG, H3 wildtype, TP53 activated
